Mirabegron Use in Post-Stroke Patients with Overactive Bladder
Mirabegron can be used safely in stroke patients with overactive bladder, provided their blood pressure is controlled (<140/90 mmHg) and eGFR >30 mL/min/1.73 m², with regular blood pressure monitoring required during treatment. 1
Blood Pressure Considerations
The FDA label explicitly states that mirabegron is not recommended for patients with severe uncontrolled hypertension (systolic BP ≥180 mmHg and/or diastolic BP ≥110 mmHg), but does not contraindicate its use in patients with controlled hypertension or history of stroke. 1
Blood Pressure Monitoring Requirements
- Periodic blood pressure determinations are mandatory, especially in hypertensive patients, as mirabegron can increase blood pressure. 1
- In clinical trials of OAB patients, mirabegron 50 mg increased systolic/diastolic BP by approximately 0.5-1 mmHg compared to placebo. 1
- Real-world data shows that 20% of patients may experience SBP increases ≥10 mmHg, with older patients (≥65 years) at higher risk (23.4% vs 7.4% in younger patients). 2
Stroke-Specific Safety Evidence
Direct evidence supports mirabegron's safety in post-stroke patients:
- A prospective randomized study specifically evaluated mirabegron in patients with history of cerebrovascular accident (CVA) who had stable neurological status for at least 3 months. 3
- After 3 months of treatment, mirabegron showed no deterioration in cognitive function as measured by Montreal Cognitive Assessment scores and was both safe and effective for OAB symptoms. 3
- A separate study in elderly OAB patients with CNS lesions (including CVA, Parkinson's disease, and dementia) demonstrated that low-dose mirabegron (25 mg) effectively decreased urgency symptoms with mild adverse events in only a few cases. 4
Cardiovascular Safety Profile
Large-scale cardiovascular safety analysis of 13,396 patients found:
- The frequency of cardiovascular adverse events was comparable between mirabegron (0.4-1.5%) and placebo (0.9%). 5
- Baseline cardiovascular risk factors (history of arrhythmia, coronary artery disease, and stroke/TIA) were significantly associated with subsequent CV events, whereas mirabegron therapy was not. 5
- Changes in blood pressure did not confer increased risk of cardiovascular adverse events. 5
Practical Management Algorithm
Patient Selection Criteria
- Stable neurological status for ≥3 months post-stroke 3
- Blood pressure <140/90 mmHg (based on ESC guidelines for post-stroke BP management) 6
- eGFR >30 mL/min/1.73 m² 1
- No severe uncontrolled hypertension (BP <180/110 mmHg) 1
Dosing Strategy
- Start with 25 mg once daily 1, 3, 4
- After 4-8 weeks, may increase to 50 mg once daily if needed and BP remains controlled 1
- Take with water, swallow whole (do not crush or chew) 1
Monitoring Protocol
- Measure blood pressure at baseline, 4 weeks, 12 weeks, and periodically thereafter 1, 2
- Monitor for signs of urinary retention if patient has bladder outlet obstruction 1
- Assess cognitive function if concerns arise, though deterioration is not expected 3
Important Caveats
Timing after stroke matters: The ESC guidelines recommend that for stable patients who remain hypertensive (≥140/90 mmHg) ≥3 days after acute ischemic stroke, initiation or reintroduction of BP-lowering medication is appropriate. 6 This aligns with the stroke study requirement of ≥3 months stability before starting mirabegron. 3
Renal dosing adjustments: For patients with eGFR 15-29 mL/min/1.73 m², maximum dose should not exceed 25 mg once daily; mirabegron is not recommended for eGFR <15 mL/min/1.73 m². 1
Drug interactions: Mirabegron is a moderate CYP2D6 inhibitor, requiring dose adjustment of narrow therapeutic index drugs metabolized by CYP2D6 (e.g., certain antiarrhythmics, antidepressants). 1 Monitor digoxin levels if co-administered. 1
Alternative consideration: The AUA/SUFU guidelines support β3-adrenoceptor agonists as second-line therapy for OAB, and combination therapy with antimuscarinics may be considered for refractory cases. 7